Serveur d'exploration Stress et Covid

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

The localization of topoisomerase II cleavage sites on DNA in the presence of antitumor drugs

Identifieur interne : 000340 ( France/Analysis ); précédent : 000339; suivant : 000341

The localization of topoisomerase II cleavage sites on DNA in the presence of antitumor drugs

Auteurs : Claude Paoletti [France]

Source :

RBID : ISTEX:E27569C4F23EF52B777A29D9B7190E8F67533A59

English descriptors

Abstract

Abstract: Type II topoisomerase are enzymes that break and religate DNA phophodiester bonds while crossing over DNA strands and altering DNA topology. They also structural proteins that play a role in the spatial organization of chromatin and are involved in several crucial biological functions, such as DNA replication and transcription, chromosome segregation and recombination.Many drugs interfere with type II topoisomerases and can be assigned to two main groups. Coumarin derivatives and synthetic quinolones act at the level of ATP binding or hydrolysis and are used for controlling bacterial infections. Drugs belonging to the second group produce DNA lesions by trapping a “cleavable complex” consisting of the normal transient topoisomerase II-DNA reaction intermediate in which the enzyme and the DNA are joined by two covalent bonds. There are four main categories of antitumour drugs that form cleavable complexes in eukaryotes: acridines, anthraccclines, ellipticines and epipodophyllotoxins. These drugs are cytotoxic and many—but not all—are endowed with antitumoral properties. The mechanisms of this pharmacological activity are not understood.Topoisomerase II-induced DNA breaks generated from cleavable complexes display different levels of cytotoxicity depending on their localization on DNA. The primary structure of DNA is not the only parameter that determines this localization. The spatial organization of the enzyme-DNA complex and both the topology and the structure of the underlying chromatin fiber constitute additional critical factors. It, therefore, may be unrealistic to expect that the actual pharmacological potency of antitumor drugs that act on type II topoisomerases can be accurately predicted solely on the basis of simple in vitro test tube experiments carried out using pure enzymes and naked DNA.

Url:
DOI: 10.1016/0163-7258(93)90018-9


Affiliations:


Links toward previous steps (curation, corpus...)


Links to Exploration step

ISTEX:E27569C4F23EF52B777A29D9B7190E8F67533A59

Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title>The localization of topoisomerase II cleavage sites on DNA in the presence of antitumor drugs</title>
<author>
<name sortKey="Paoletti, Claude" sort="Paoletti, Claude" uniqKey="Paoletti C" first="Claude" last="Paoletti">Claude Paoletti</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:E27569C4F23EF52B777A29D9B7190E8F67533A59</idno>
<date when="1994" year="1994">1994</date>
<idno type="doi">10.1016/0163-7258(93)90018-9</idno>
<idno type="url">https://api.istex.fr/ark:/67375/6H6-W43R6R7D-0/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001019</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001019</idno>
<idno type="wicri:Area/Istex/Curation">000F84</idno>
<idno type="wicri:Area/Istex/Checkpoint">001B48</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001B48</idno>
<idno type="wicri:doubleKey">0163-7258:1994:Paoletti C:the:localization:of</idno>
<idno type="wicri:Area/Main/Merge">003309</idno>
<idno type="wicri:Area/Main/Curation">003298</idno>
<idno type="wicri:Area/Main/Exploration">003298</idno>
<idno type="wicri:Area/France/Extraction">000340</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a">The localization of topoisomerase II cleavage sites on DNA in the presence of antitumor drugs</title>
<author>
<name sortKey="Paoletti, Claude" sort="Paoletti, Claude" uniqKey="Paoletti C" first="Claude" last="Paoletti">Claude Paoletti</name>
<affiliation wicri:level="3">
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Gustave Roussy, 94800—Villejuif</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Île-de-France</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Pharmacology and Therapeutics</title>
<title level="j" type="abbrev">JPT</title>
<idno type="ISSN">0163-7258</idno>
<imprint>
<publisher>ELSEVIER</publisher>
<date type="published" when="1993">1993</date>
<biblScope unit="volume">60</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="381">381</biblScope>
<biblScope unit="page" to="387">387</biblScope>
</imprint>
<idno type="ISSN">0163-7258</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0163-7258</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="Teeft" xml:lang="en">
<term>Antitumor</term>
<term>Antitumor drugs</term>
<term>Basic understanding</term>
<term>Biol</term>
<term>Catalytic cycle</term>
<term>Chemical processes</term>
<term>Chromatin</term>
<term>Chromatin opening</term>
<term>Chromatin structure</term>
<term>Chromosome</term>
<term>Chromosome segregation</term>
<term>Cleavable</term>
<term>Cleavable complexes</term>
<term>Cleavage</term>
<term>Cleavage sites</term>
<term>Coumarin derivatives</term>
<term>Covalent bonds</term>
<term>Double helix</term>
<term>Eukaryotic</term>
<term>Eukaryotic cells</term>
<term>Eukaryotic type</term>
<term>Form cleavable complexes</term>
<term>Localization</term>
<term>Main categories</term>
<term>Mammalian topoisomerase</term>
<term>Nucleotide</term>
<term>Nucleotide sequences</term>
<term>Other hand</term>
<term>Other proteins</term>
<term>Phosphodiester bonds</term>
<term>Primary structure</term>
<term>Protein kinase</term>
<term>Second group</term>
<term>Sequence specificity</term>
<term>Spatial organization</term>
<term>Structural proteins</term>
<term>Topoisomerase</term>
<term>Topoisomerases</term>
<term>Wang</term>
<term>Yeast strains</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Abstract: Type II topoisomerase are enzymes that break and religate DNA phophodiester bonds while crossing over DNA strands and altering DNA topology. They also structural proteins that play a role in the spatial organization of chromatin and are involved in several crucial biological functions, such as DNA replication and transcription, chromosome segregation and recombination.Many drugs interfere with type II topoisomerases and can be assigned to two main groups. Coumarin derivatives and synthetic quinolones act at the level of ATP binding or hydrolysis and are used for controlling bacterial infections. Drugs belonging to the second group produce DNA lesions by trapping a “cleavable complex” consisting of the normal transient topoisomerase II-DNA reaction intermediate in which the enzyme and the DNA are joined by two covalent bonds. There are four main categories of antitumour drugs that form cleavable complexes in eukaryotes: acridines, anthraccclines, ellipticines and epipodophyllotoxins. These drugs are cytotoxic and many—but not all—are endowed with antitumoral properties. The mechanisms of this pharmacological activity are not understood.Topoisomerase II-induced DNA breaks generated from cleavable complexes display different levels of cytotoxicity depending on their localization on DNA. The primary structure of DNA is not the only parameter that determines this localization. The spatial organization of the enzyme-DNA complex and both the topology and the structure of the underlying chromatin fiber constitute additional critical factors. It, therefore, may be unrealistic to expect that the actual pharmacological potency of antitumor drugs that act on type II topoisomerases can be accurately predicted solely on the basis of simple in vitro test tube experiments carried out using pure enzymes and naked DNA.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>France</li>
</country>
<region>
<li>Île-de-France</li>
</region>
</list>
<tree>
<country name="France">
<region name="Île-de-France">
<name sortKey="Paoletti, Claude" sort="Paoletti, Claude" uniqKey="Paoletti C" first="Claude" last="Paoletti">Claude Paoletti</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000340 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000340 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    StressCovidV1
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     ISTEX:E27569C4F23EF52B777A29D9B7190E8F67533A59
   |texte=   The localization of topoisomerase II cleavage sites on DNA in the presence of antitumor drugs
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed May 6 16:44:09 2020. Site generation: Sun Mar 28 08:26:57 2021